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Objectives: Since 2008, the Caisse Nationale d’Assurance Maladie des Travailleurs 
Salariéshas set up a diabetic patient support programme in ten pilot depart-
ments in France. In addition to written advice, programme members also have 
access to telephone support from health education nurses. In 2010, the sophia 
programme was extended to another nine departments and, at the beginning of 
2013, it was generalized to all French departments. The present study evaluated 
the health economics impact of the programme after a follow-up of 3 years. This 
analysis follows a preliminary assessment that demonstrated positive results 
after 1 year. MethOds: The variation of various health care use indicators as 
well as outpatient and inpatient costs was compared between three cohorts: 
members of pilot departments, non-members, and a control group of diabetic 
patients living in departments in which sophia was not available. Results are 
adjusted for between-group differences observed at the beginning of the pro-
gramme. Results: Adjusted analysis showed that, after matching for all other 
characteristics, compliance with recommended examinations improved to a much 
greater extent among programme members than among control subjects and 
non-members. Although all health care costs continued to increase in each cohort, 
outpatient and inpatient expenditure was € 226 lower for programme members 
than for controls for the period 2009-2011: -€ 54 for outpatient care and -€ 172 
for inpatient care. Although the outpatient expenditure of programme members 
was higher (+€ 40) for outpatient visits and medical procedures, their paramedical 
expenditure was lower (-€ 89). Hospitalization rates for diabetes were significantly 
lower among members than among controls. cOnclusiOns: These results con-
firm the significant impact of the sophia programme on compliance with clinical 
practice guidelines in diabetology, hospitalization rates, and the 3-year growth of 
outpatient and inpatient costs. An assessment of the impact of the sophia pro-
gramme on clinical parameters will be conducted in the near future.
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Objectives: To evaluate the consistency of T2DM management by French GPs in 
2012 versus 2013 HAS guidelines that recommend modulating glycaemic objec-
tives depending on patient’s profile. To assess current treatment need for T2DM 
patients. MethOds: A transversal study, based on the IMS LifeLinkTM prospective 
Diabetes Cohort linked to Electronic Medical Records database (Disease Analyzer) 
was used to investigate patients’ profiles (age, disease history and complications, 
renal impairment, cardiovascular events, co-morbidities), HbA1c, hypoglycaemic 
risk, self monitoring of blood glucose (SMBG), and BMI evolution, linked to the cur-
rent treatment. Results: A total of 6680 T2DM patients (56% men) were included 
in the 2012 study cohort. The mean age was 66.6 years (25% of patients above 75 
years); 19% had moderate to severe renal impairment and 56% had cardiovascular 
history. The new HAS guidelines split patients into several categories with associ-
ated HbA1c objectives varying from 6.5% to 9% based on age, frailty, diabetes history, 
and co-morbidities. 4%, 35%, 43%, and 18% of diabetic patients were eligible for the 
6.5%, 7%, 8%, and 9% HbA1c objectives respectively. It appears that 55% of the dia-
betic population were at risk of hypoglycaemia, age and long diabetes history being 
the major risk factors. Given the modulation of glycaemic objectives more patients 
reached the new HbA1c objectives (74% of patients) vs. previous guidelines (about 
55%). In this representative cohort, SU were prescribed with no dosage adjustment 
to all patients and even more frequently to patients at risk of hypoglycaemia (60.6%) 
while DDP4i were prescribed to “healthy patients” mostly not at risk of hypoglycae-
mia (51.5%). cOnclusiOns: A minority of T2DM patients (39%) are eligible for an 
HbA1c objective of 7% or below, highlighting their frailty. This survey also shows that 
more patients are reaching their HbA1c target. However many of them are receiving 
treatments they should not due to high risk of hypoglycaemia.
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Objectives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. This study examines 
these impacts in Germany and compares findings to data from US, UK, Canada 
and China. MethOds: A 5 country web-based survey was conducted. MPs were 
defined as: unintentionally forgetting to take insulin (UF), questioning if insulin 
had been taken (QT), or questioning amount of dose (QD). Results: A total of 350 
German respondents (60.0% Type 1) completed the survey, 61.1% male, mean age of 
39.5 (±13.3) and mean age of diabetes onset 30.2 (±12.6). The prevalence of MPs in the 
past month was: 74.0% UF, 82.0% QT and 68.3% QD. MPs occurred most frequently 
when waking in the morning or when relaxing. Between 27.9% (UF) – 48.3% (QD) of 
respondents skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP. Patients experiencing MPs required between 2.0 (QT)–8.7 (UF) 
hours, on average, to return to normal blood glucose range, conducted between 1.2 
(QT) –4.4 (UF) extra BG monitoring tests, reported a moderate negative impact on 
their physical and emotional functioning, work absenteeism or reduced ability to 
function optimally when at work and between 3.6% (QT) and 13.8% (QD) visited/
contacted their health care provider due to MPs. Compared to the total sample 
(N= 1404), German respondents were more likely to report that their diabetes was 
very well/well controlled and that they were very/extremely confident in knowing 
what to do when they had an MP compared to respondents and were less likely 
than patients in other countries to have contact with a physician or other health 
care professional following a MP. cOnclusiOns: These findings suggest that MPs 
and 14/12% (N/D) contacted a health care professional. In the week after an event, 
respondents added an average of 2.8/3.6 (N/D) blood glucose tests to an average of 
18.8/17.4 (N/D) tests in a normal week. Nocturnal events had a high impact on sleep 
quality (46% of respondents) and social life (24%), and 84% of respondents felt tired 
and/or fatigued the next day. In the daytime survey, about 26% reported the event 
highly impacted daily activities (outside of work). Also, 40/18% (N/D) of respondents 
indicated that the event had a high impact on their fear of hypoglycaemia. The 
majority ascribed hypoglycaemia to stress (50%/58% [N/D]) or irregular/insufficient 
food intake (50%/40% [N/D]). cOnclusiOns: Both nocturnal and daytime hypogly-
caemic events had an impact on patients’ use of health care system, quality of life 
and daily productivity.
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Objectives: To investigate the clinical significance of change in QoL-AGHDA 
score after 1 year of growth hormone (GH) replacement. MethOds: Observational 
data were obtained from KIMS (Pfizer International Metabolic Database). Minimal 
important differences (MID) for the QoL-AGHDA score and its five domains (mem-
ory and concentration, tenseness, tiredness, self-confidence, and social isolation) 
were calculated using an anchor-based approach with a rating of patient-perceived 
treatment benefit and patient-reported change in need for assistance. Perception 
of treatment benefit was measured using the KIMS Patient Life Situation Form 
(PLSF), a 5-point ordinal assessment of change (much improved, a little improved, 
no change, a little worse, much worse). The effect of baseline (BL) scores on MID 
was analysed using the QoL-AGHDA thresholds included in the New Zealand (≥ 16) 
and England (≥ 11) reimbursement criteria. Results: Data from 1404 patients 
(52% female, 96% Caucasian, mean age [SD] of 45 [14] years) were included in the 
analysis. Mean GH dose [SD]was 0.20 [0.14] mg/day at BL and 0.32 [0.16] mg/day 
during Year 1. The Spearman correlation between change in QoL-AGHDA score 
and perception of treatment benefit was moderately positive (0.45; p < 0.01). The 
correlation was stronger for females and for patients with more impaired (higher) 
BL QoL-AGHDA scores. Using the anchor-based approach with patient-perceived 
treatment benefit, the MID for the QoL-AGHDA score was -4.61 at Year 1. Self-
confidence was most sensitive and tenseness least sensitive of the domains in 
predicting patient-perceived treatment benefit. Patients requiring assistance at 
BL and not at Year 1 experienced the largest mean improvement in QoL-AGHDA 
score. cOnclusiOns: Several national reimbursement authorities currently 
include the QoL-AGHDA score in eligibility criteria for access to reimbursed GH 
replacement. This is the first study to calculate the MID for the QoL-AGHDA score. 
Findings indicate that change in QoL-AGHDA score is positively correlated with 
patient-perceived treatment benefit.
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Objectives: This study examined the effects of nocturnal and daytime non-severe 
hypoglycaemic events on utilisation of health care services and patient quality of 
life in Brazil. MethOds: People with diabetes from six different countries who 
had experienced a non-severe hypoglycaemic event in the past 4 weeks were 
asked to take part in a nocturnal and/or daytime hypoglycaemia survey. In the 
Brazilian subgroup, 86 people responded (50 respondents per survey). The sur-
veys were conducted either face to face or online; hypoglycaemic events were 
self-reported. Results: In the Brazilian cohort (nocturnal [N]/daytime [D] survey, 
respectively), 80% (N)/76% (D) had type 2 diabetes, 46%/38% (N/D) were male, mean 
age was 41(N)/40(D) years and mean weight was 82.4 kg(N)/81.8 kg (D). Participants 
received treatment with insulin (53%/70% [N/D]), oral medication (61%/60% [N/D]), 
GLP-1 (0%/8% [N/D]) and/or diet and exercise (32%/45% [N/D]). Approximately a 
quarter of respondents (26%/22% [N/D]) reported that they generally experienced 
a hypoglycaemic episode at least once a week. After the non-severe nocturnal (N)/
daytime (D) hypoglycaemic event, 29% and 53% (N/D) decreased their insulin dose 
and 38% and 50%, respectively, contacted a health care professional. Participants 
used on average 13.0 or 11.5 (N/D) extra blood glucose tests the following week and 
56%/32% (N/D) of the surveyed reported a high level of fear of a hypoglycaemic event. 
Among the 44/43 (N/D) respondents who worked for pay, 48%/35% (N/D) went to 
work late or left early; 23%/9% (N/D) missed ≥ 1 full days due to the non-severe event 
and 55%/26% (N/D) said that the event highly impacted upon their productivity at 
work. cOnclusiOns: In Brazil, nocturnal and daytime non-severe hypoglycaemic 
events severely impact upon patients’ quality of life and work productivity, with half 
of patients surveyed decreasing their insulin dose and/or contacting their health 
care provider after a non-severe event.
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